Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Prediction of prostate cancer clinical outcome remains a major challenge after diagnosis. Several high throughput approaches
were applied to analyze the genome abnormalities of prostate cancer. To evaluate whether copy number variation (CNV) of
genomes in prostate cancer (T), benign prostate tissues adjacent to tumor (AT) and blood of prostate cancer patients predicts
biochemical (PSA) relapse and the kinetics of relapse, 241 samples were analyzed through Affymetrix SNP 6.0 chips. Using
gene specific CNV from T, the genome model correctly predicted 73% cases for relapse and 75% for short PSADT. The gene
specific CNV model from AT correctly predicted 67% cases for relapse and 77% for short PSADT. Using median size of
CNV from blood, the genome model correctly predicted 81% for relapse and 69% for short PSADT. To analyze epigenome
abnormalities of prostate cancer, genome wide methylation analyses were performed using both array and whole genome
methylation sequencing approaches for 91 human prostate specimens. A gene methylation prediction model was shown
to predict prostate cancer relapse with sensitivity of 80.0% and specificity of 85.0%. Through whole genome methylation
sequencing, we found both intragene and promoter CpG islands contributed to the suppression of RNA transcription. Most of
the differential methylation between T and AT occurred in regions outside the CpG islands. Our analysis indicates that genome
or epigenome abnormalities of benign or malignant tissues are predictive of clinical outcome of a malignancy.
Biography
Jianhua Luo been studying molecular pathology related to human malignancies in the last 23 years. Currently, he is a Professor of Pathology and Director of
High Throughput Genome Center at University of Pittsburgh. In the last 13 years, Dr. Luo has been largely focusing on genetic and molecular mechanism of
human prostate and hepatocellular carcinomas. In this period, his group has identified and characterized several genes that are related to prostate cancer and
hepatocellular carcinoma, including SAPC, myopodin, CSR1, GPx3, ITGA7, MCM7, MT1h and GPC3. He has characterized several signaling pathways that play
critical role in prostate cancer development, including Myopodin-ILK-MCM7 inhibitory signaling, myopodin-zyxin motility inhibition pathway, CSR1-CPSF3 and
CSR1-XIAP apoptotic pathways, MT1h-EHMT1 egigenomic signaling, ITGA7-HtrA2 tumor suppression pathway, GPx3-PIG3 cell death pathway, and AR-MCM7
oncogenic pathway. He proposed prostate cancer field effect in 2002. He is one of the pioneers in utilizing high throughput gene expression and genome analyses
to analyze field effects in prostate cancer and liver cancer. He is also the first in using methylation array to analyze prostate cancer. Recently, Dr. Luo?s group
found that patterns of copy number variants of certain specific genome loci, are predictive of prostate cancer clinical outcomes, regardless tissue origin. Overall,
these findings advance our understanding on how cancer develops and behaves, and lay down the foundation for better future diagnosis and treatment of human
malignancies.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 
